Skip to main navigation Skip to search Skip to main content

A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

  • Guy Pratt
  • , Christina Yap
  • , Ceri Oldreive
  • , Daniel Slade
  • , Rebecca Bishop
  • , Mike Griffiths
  • , Martin J S Dyer
  • , Chris Fegan
  • , David Oscier
  • , Andrew Pettitt
  • , Estella Matutes
  • , Stephen Devereux
  • , David Allsup
  • , Adrian Bloor
  • , Peter Hillmen
  • , George Follows
  • , Simon Rule
  • , Paul Moss
  • , Tatjana Stankovic

Research output: Contribution to journal › Letter › peer-review

7 Citations (Scopus)
503 Downloads (Pure)
Original languageEnglish
Pages (from-to)429-433
JournalBritish Journal of Haematology
Volume182
Issue number3
Early online date23 Jun 2017
DOIs
Publication statusPublished - Aug 2018

Keywords

  • Letter
  • chronic lymphocytic leukaemia
  • mantle cell lymphoma
  • DNA damage
  • olaparib

Access to Document

  • Pratt_et_al_A_multi-centre_phase_I_trial_British_Journal_of_Haematology_2017

    This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

    Accepted author manuscript, 97.7 KBLicence: Other (please specify with Rights Statement)
  • Pratt_et_al_A_multi-centre_phase_I_trial_British_Journal_of_Haematology_2017_Additional_documents_1

    This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

    Accepted author manuscript, 15.4 KBLicence: Other (please specify with Rights Statement)
  • Pratt_et_al_A_multi-centre_phase_I_trial_British_Journal_of_Haematology_2017_Additional_documents_2

    This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. Br J Haematol. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

    Accepted author manuscript, 28.9 KBLicence: Other (please specify with Rights Statement)

    Cite this